Wednesday, January 17, 2024

Imipenam (carbapenam).. Inhibition of bacterial cell wall synthesis by binding to penicillin-binding proteins

Imipenam (carbapenam):

Imipenem is indeed the first thienamycin ß-lactam antibiotic. It was developed in the 1970s by Merck and Co. and revolutionized antibiotic treatment due to its broad spectrum of activity against both Gram-positive and Gram-negative bacteria, including many multidrug-resistant strains.

Additional Points:

Here are some additional points about imipenem:

- Mechanism of action:

Like other β-lactam antibiotics, imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

- Clinical uses:

Imipenem is typically used to treat serious infections caused by multidrug-resistant bacteria, such as those affecting the respiratory tract, abdomen, pelvis, and skin.

- Limitations:

Imipenem has several limitations, including potential for serious side effects like seizures and allergic reactions. It is also rapidly inactivated by human kidney enzymes, requiring co-administration with cilastatin, which inhibits these enzymes.

- Importance:

Despite its limitations, imipenem remains an important antibiotic for treating severe infections and continues to be a valuable tool in the fight against antimicrobial resistance.